Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
British Journal of Pharmacology
|
October 5, 2024
Anti-inflammatory and remyelinating effects of fexagratinib in experimental multiple sclerosis
Fynn Gurski, Kian Shirvanchi, Vinothkumar Rajendran, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
October 10, 2013
Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial
Sascha Köpke, Simone Kern, Tjalf Ziemssen, et al.
Neurogenetics
|
July 25, 2018
The polynucleotide kinase 3'-phosphatase gene (PNKP) is involved in Charcot-Marie-Tooth disease (CMT2B2) previously related to MED25
Alejandro Leal, Sixto Bogantes-Ledezma, Arif B Ekici, et al.
Clinical Imaging
|
July 16, 2016
Factors influencing intracranial vessel densities on unenhanced computed tomography: differences between hemispheres
Astrid E Grams, Rafael Rehwald, Charlotte Schmittnägel, et al.
Neurogenetics
|
July 8, 2003
Charcot-Marie-Tooth disease: a novel Tyr145Ser mutation in the myelin protein zero (MPZ, P0) gene causes different phenotypes in homozygous and heterozygous carriers within one family
Alejandro Leal, Corinna Berghoff, Martin Berghoff, et al.
British Journal of Pharmacology
|
July 4, 2023
The small molecule fibroblast growth factor receptor inhibitor infigratinib exerts anti-inflammatory effects and remyelination in a model of multiple sclerosis
Ranjithkumar Rajendran, Vinothkumar Rajendran, Gregor Böttiger, et al.
Neurogenetics
|
December 10, 2014
Identification of the variant Ala335Val of MED25 as responsible for CMT2B2: molecular data, functional studies of the SH3 recognition motif and correlation between wild-type MED25 and PMP22 RNA levels in CMT1A animal models
Alejandro Leal, Kathrin Huehne, Finn Bauer, et al.
Neurogenetics
|
March 18, 2009
Identification of the variant Ala335Val of MED25 as responsible for CMT2B2: molecular data, functional studies of the SH3 recognition motif and correlation between wild-type MED25 and PMP22 RNA levels in CMT1A animal models
Alejandro Leal, Kathrin Huehne, Finn Bauer, et al.
Journal of Neurology
|
March 22, 2022
Decline in the number of patients with meningitis in German hospitals during the COVID-19 pandemic
Stefanie Völk, Markus Pfirrmann, Uwe Koedel, et al.
Der Nervenarzt
|
July 23, 2021
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]
Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
British Journal of Pharmacology
|
October 5, 2024
Anti-inflammatory and remyelinating effects of fexagratinib in experimental multiple sclerosis
Fynn Gurski, Kian Shirvanchi, Vinothkumar Rajendran, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
October 10, 2013
Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial
Sascha Köpke, Simone Kern, Tjalf Ziemssen, et al.
Neurogenetics
|
July 25, 2018
The polynucleotide kinase 3'-phosphatase gene (PNKP) is involved in Charcot-Marie-Tooth disease (CMT2B2) previously related to MED25
Alejandro Leal, Sixto Bogantes-Ledezma, Arif B Ekici, et al.
Clinical Imaging
|
July 16, 2016
Factors influencing intracranial vessel densities on unenhanced computed tomography: differences between hemispheres
Astrid E Grams, Rafael Rehwald, Charlotte Schmittnägel, et al.
Neurogenetics
|
July 8, 2003
Charcot-Marie-Tooth disease: a novel Tyr145Ser mutation in the myelin protein zero (MPZ, P0) gene causes different phenotypes in homozygous and heterozygous carriers within one family
Alejandro Leal, Corinna Berghoff, Martin Berghoff, et al.
British Journal of Pharmacology
|
July 4, 2023
The small molecule fibroblast growth factor receptor inhibitor infigratinib exerts anti-inflammatory effects and remyelination in a model of multiple sclerosis
Ranjithkumar Rajendran, Vinothkumar Rajendran, Gregor Böttiger, et al.
Neurogenetics
|
December 10, 2014
Identification of the variant Ala335Val of MED25 as responsible for CMT2B2: molecular data, functional studies of the SH3 recognition motif and correlation between wild-type MED25 and PMP22 RNA levels in CMT1A animal models
Alejandro Leal, Kathrin Huehne, Finn Bauer, et al.
Neurogenetics
|
March 18, 2009
Identification of the variant Ala335Val of MED25 as responsible for CMT2B2: molecular data, functional studies of the SH3 recognition motif and correlation between wild-type MED25 and PMP22 RNA levels in CMT1A animal models
Alejandro Leal, Kathrin Huehne, Finn Bauer, et al.
Journal of Neurology
|
March 22, 2022
Decline in the number of patients with meningitis in German hospitals during the COVID-19 pandemic
Stefanie Völk, Markus Pfirrmann, Uwe Koedel, et al.
Der Nervenarzt
|
July 23, 2021
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]
Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Page
of 5